Gemtuzumab ozogamicin (Mylotarg) has been recommended for approval in Europe for use in acute myeloid leukemia, but adjuvant sunitinib after kidney cancer surgery was turned down.International Approvals
Publication date: Available online 26 January 2018 Source:The Lancet Haematology Author(s): Paul M Barr, Hongli Li, W Richard Burack, Michael LeBlanc, Sonali M Smith, Ajay K Gopal, Justin D Floyd, Daniel O Persky, Oliver W Press, Richard I Fisher, Jonathan W Friedberg Background Despite an abundance of therapeutic options, advanced-stage follicular lymphoma remains incurable. Furthermore, the ideal sequence and absolute benefit of post-induction therapy is unclear. We designed SWOG S0801 to assess the efficacy and safety of consolidative radioimmunotherapy and sequential maintenance rituximab following chemoimmunotherapy….
Conclusion Bendamustine is an effective therapy with limited long-term sequelae in patients with lymphoid malignancies. Micro-Abstract Bendamustine is an effective treatment for lymphoid malignancies and its role continues to expand. To determine the long-term sequelae associated with bendamustine, 194 patients treated with bendamustine (most commonly with rituximab) were retrospectively reviewed. The rate of secondary malignancies was minimal and no therapy-related myelodysplastic syndrome or acute myelogenous leukemia were reported. No deaths from infection were attributable to bendamustine.
Author Affiliations open
1 McLaughlin Centre for Population Health Risk Assessment, University of Ottawa, Ottawa, Canada
2 Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain
3 Universitat Pompeu Fabra (UPF), Barcelona, Spain
4 CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
5 School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, Canada
6 Epidemiology Research Program, American Cancer Society, Atlanta, Georgia, USA
7 Department of Economics, Brigham Young University, Provo, Utah, USA
8 Population Studies Division, Health Canada, Ottawa, Cana…
Conclusion Bendamustine is an effective therapy with limited long-term sequelae in patients with lymphoid malignancies. Teaser Bendamustine is an effective treatment for lymphoid malignancies and its role continues to expand. In order to determine the long-term sequelae associated with bendamustine, 194 patients treated with bendamustine (most commonly with rituximab) were retrospectively reviewed. The rate of secondary malignancies was minimal and no therapy-related myelodysplastic syndrome or acute myelogenous leukemia were reported. No deaths from infection were attributable to bendamustine.
Background: Nivolumab is a programmed cell death-1 receptor (PD-1) inhibitor approved by the U.S. Food and Drug Administration for the treatment of melanoma, non-small cell lung cancer, renal cancer, and classical Hodgkin lymphoma. For patients on immune checkpoint modulators such as PD-1 inhibitors, cutaneous immune-related adverse events (irAEs) are a significant concern. Dermatologic toxicities include pruritus, vitiligo, eczema, lichenoid eruptions and Stevens-Johnson syndrome. Vitiligo-like depigmentation has been well described in melanoma patients receiving treatment with PD-1 inhibitors.
This article will also review different generations of immunotoxins with special focus on immunotoxins which are under clinical trials or approved for clinical use. Finally, current deimmunization strategies for development of new less-immunogenic recombinant immunotoxins will be discussed.
ABBREVIATIONS: mAbs: Monoclonal antibodies; EF2: elongation factor 2; ITs: Immunotoxins; DT: Diphtheria toxin; PE: Pseudomonas exotoxin; dgA: de-glycosylated A-chain of ricin; rGel: recombinant de-glycosylated form of gelonin; NKC: natural killer cells; HTR: human transferrin receptor; EGF: epidermal growth factor; GM-CSF: granulocy…
Myeloid ecotropic viral integration site 1 (MEIS1) protein plays a synergistic causative role in acute myeloid leukemia (AML). However, MEIS1 has also shown to be a potential tumor suppressor in some other can…
Did you smoke? That is often one of the first responses patients hear when they tell people about their lung cancer diagnosis. For decades lung cancer has been singled out as THE smoker’s disease, despite evidence that over 30 other deadly diseases are directly linked to tobacco consumption. In fact, a recent study published in the New England Journal of Medicine found that breast cancer, prostate cancer, kidney failure and diabetes are among those smoking-related diseases. This connection between tobacco and serious illnesses other than lung cancer has been known for quite a while. The U.S. surgeon general lists smoking …
The Senate Veterans Affairs Committee heard testimony on Tuesday from senators and advocates who urged the U.S. Department of Veterans Affairs to remove roadblocks to care and compensation for veterans sickened by environmental toxicants, including contaminated drinking water at North Carolina’s Camp Lejeune. “Agents within the VA system have expended more effort, time and money devising methods to deny Camp Lejeune victims their rightful benefits rather than providing them,” Retired Master Sgt. Jerry Ensminger, who has devoted nearly 18 years to research and advocacy on the issue, said in his testimony before th…
Aberrant activation or disruption of autophagy promotes tumorigenesis in various preclinical models of cancer, but whether the autophagy pathway is a target for recurrent molecular alteration in human cancer patient samples is unknown. To address this outstanding question, we surveyed 211 human autophagy-associated genes for tumor-related alterations to DNA sequence and RNA expression levels and examined their association with patient survival outcomes in multiple cancer types with sequence data from The Cancer Genome Atlas consortium. We found 3 (RB1CC1/FIP200, ULK4, WDR45/WIPI4) and one (ATG7) core auto…